GO:1901224 positive regulation of non-canonical NF-kappaB signal transduction: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1901224 describes any process that activates or increases the frequency, rate or extent of the non-canonical NF-kappaB cascade, a signaling pathway centered on NIK, IKKalpha, and p52.
• The non-canonical NF-kappaB pathway is distinct from the canonical pathway and is critical for lymphoid organogenesis, B-cell maturation, and immune responses.
• Deregulation of this pathway is a hallmark of lymphoid malignancies, including Hodgkin lymphoma and non-Hodgkin lymphoma.
• The pathway is dynamically modulated in HIV infection and is being explored for shock-and-kill strategies to purge latent reservoirs.
• Impaired non-canonical NF-kappaB signaling is associated with disseminated tuberculosis and compromised T cell immunity.
• Recent evidence links non-canonical NF-kappaB activation to colorectal cancer progression and anti-PD-1 resistance through S100A14-UPF1 signaling.
Description
The non-canonical NF-kappaB signaling cascade is a distinct branch of the NF-kappaB pathway that governs diverse biological processes, including lymphoid organ development, B-cell survival, and immune cell activation. Unlike the canonical pathway, which relies on IKKbeta and rapid IkappaBalpha degradation, the non-canonical pathway depends on the accumulation of NF-kappaB-inducing kinase (NIK) and the subsequent activation of IKKalpha, leading to the processing of p100 into p52 and nuclear translocation of p52-RelB dimers. GO:1901224, positive regulation of non-canonical NF-kappaB signal transduction, captures the upstream events that enhance this cascade, such as ligand-induced stabilization of NIK or increased expression of pathway components. Researchers study this term because its dysregulation is causally linked to hematological malignancies, immune deficiencies, and infectious diseases. For example, constitutive activation of the non-canonical pathway is a hallmark of Hodgkin lymphoma and non-Hodgkin lymphoma, where it drives survival and proliferation of malignant cells. In HIV infection, pharmacological modulation of the pathway is being explored to reactivate latent virus for elimination. Moreover, impaired non-canonical NF-kappaB signaling has been observed in disseminated tuberculosis, linking it to T cell exhaustion. Thus, understanding the positive regulation of this pathway is essential for developing targeted therapies and immunomodulatory strategies.
positive regulation of non-canonical NF-kappaB signal transduction At A Glance
| GO ID | GO:1901224 |
|---|---|
| GO term | positive regulation of non-canonical NF-kappaB signal transduction |
| Ontology | biological_process |
| Synonym | activation of NIK/NF-kappaB cascade; positive regulation of p52-dependent NF-kappaB signaling; upregulation of noncanonical NF-kappaB signaling |
| Major function | Enhances the non-canonical NF-kappaB cascade, leading to p52-RelB nuclear translocation and target gene expression. |
| Key upstream regulators | NIK (MAP3K14), IKKalpha (CHUK), TRAF2, TRAF3, cIAP1/2. |
| Key downstream effectors | p100/p52 (NFKB2), RelB, and target genes involved in immune regulation and cell survival. |
| Associated diseases | Hodgkin lymphoma, non-Hodgkin lymphoma, HIV latency, disseminated tuberculosis. |
What Is GO:1901224?
GO:1901224, positive regulation of non-canonical NF-kappaB signal transduction, is defined as any process that activates or increases the frequency, rate or extent of the non-canonical NF-kappaB cascade. This biological process encompasses molecular events that amplify the signaling cascade initiated by ligands such as CD40L, BAFF, or lymphotoxin-beta, ultimately leading to the activation of NF-kappaB-inducing kinase (NIK), phosphorylation and processing of p100 to p52, and nuclear translocation of p52-RelB dimers. The term includes positive regulation at any step, from receptor engagement to transcriptional activation of target genes.
Why Is positive regulation of non-canonical NF-kappaB signal transduction Important in Cell Biology?
The positive regulation of non-canonical NF-kappaB signaling is critically important because it controls key immune and survival programs, and its dysregulation contributes to a wide range of human diseases. Constitutive activation of this pathway is a driving oncogenic mechanism in several lymphoid malignancies, making it a therapeutic target. In infectious diseases, the pathway modulates HIV latency and tuberculosis immunity, offering opportunities for host-directed therapies. Furthermore, recent studies implicate non-canonical NF-kappaB activation in colorectal cancer progression and resistance to immune checkpoint blockade, highlighting its broad relevance in solid tumors. Therefore, understanding how this pathway is positively regulated is essential for basic immunology and translational medicine.
• Drives lymphoid organogenesis and B-cell maturation.
• Constitutively active in Hodgkin lymphoma and non-Hodgkin lymphoma, promoting malignant cell survival.
• Modulates HIV latency and is a target for shock-and-kill strategies.
• Impaired in disseminated tuberculosis, linking to T cell exhaustion.
• Associated with colorectal cancer progression and anti-PD-1 resistance.
• Regulates inflammatory responses through TRAF-mediated signaling.
• Potential therapeutic target for autoimmune diseases and lymphoproliferative disorders.
• Involved in fibroblast subtypes associated with immunotherapy response in immune-hot tumors.
What Happens During positive regulation of non-canonical NF-kappaB signal transduction?
Ligand-induced stabilization of NIK
In simple terms: When certain immune signals bind to receptors, they protect a key protein called NIK from being destroyed, allowing it to accumulate.
In the non-canonical NF-kappaB pathway, activation begins with the engagement of specific receptors such as CD40, BAFF-R, or lymphotoxin-beta receptor. Under resting conditions, NIK is constantly targeted for degradation by a complex containing TRAF2, TRAF3, and cIAP1/2. Upon ligand binding, TRAF3 is degraded, releasing NIK from the degradation complex and allowing NIK to accumulate. This stabilization of NIK is a critical positive regulatory step, as NIK is the central kinase that initiates downstream signaling.
Activation of IKKalpha and p100 processing
In simple terms: NIK then activates another protein called IKKalpha, which cuts a larger protein p100 into its active form p52.
Accumulated NIK phosphorylates and activates IKKalpha (CHUK). Activated IKKalpha, in turn, phosphorylates the C-terminal region of p100 (NFKB2), leading to its partial proteasomal processing to generate p52. This processing is a hallmark of non-canonical NF-kappaB activation and is tightly regulated. Positive regulation of this step can occur through increased expression or activity of NIK or IKKalpha, or through inhibition of negative regulators such as TRAF3.
Nuclear translocation of p52-RelB dimers
In simple terms: The newly formed p52 pairs with RelB and moves into the nucleus to turn on specific genes.
The processed p52 preferentially dimerizes with RelB, and this p52-RelB complex translocates to the nucleus to activate transcription of target genes involved in immune regulation, cell survival, and lymphoid organogenesis. Positive regulation of non-canonical NF-kappaB signaling enhances the nuclear import of p52-RelB dimers, often through increased processing of p100 or reduced degradation of RelB. This step is a key point of integration for various signaling inputs.
Feedback and crosstalk with other pathways
In simple terms: The pathway can be fine-tuned by other signals, and it also communicates with different cellular pathways.
Positive regulation of the non-canonical NF-kappaB pathway is subject to feedback mechanisms. For instance, TRAF3 and cIAP1/2 act as negative regulators, and their downregulation enhances pathway activation. Additionally, crosstalk with the canonical NF-kappaB pathway, MAPK pathways, and other immune signaling cascades can modulate the strength and duration of non-canonical signaling. In HIV infection, pharmacological agents that modulate these feedback loops are being investigated to reactivate latent virus.
Key Genes Involved in GO:1901224 positive regulation of non-canonical NF-kappaB signal transduction
The following genes and proteins are central to the positive regulation of non-canonical NF-kappaB signal transduction, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MAP3K14 (NIK) | Central kinase that activates IKKalpha and is stabilized upon pathway activation | Key target for inhibitors in lymphoid malignancies and HIV latency reversal |
| CHUK (IKKalpha) | Phosphorylates p100 to trigger its processing to p52 | Essential for non-canonical NF-kappaB activation; studied in lymphoma and immune disorders |
| NFKB2 (p100/p52) | Precursor protein that is processed to p52, forming dimers with RelB | Mutations or dysregulation linked to immunodeficiency and lymphoma |
| RELB | Transcription factor that partners with p52 to activate target genes | Overexpressed in Hodgkin lymphoma and other malignancies |
| TRAF2 | Adaptor protein that recruits cIAP1/2 to degrade NIK under resting conditions | Negative regulator; its loss enhances non-canonical signaling |
| TRAF3 | Adaptor protein that is degraded upon activation, releasing NIK | Degradation of TRAF3 is a key step in pathway activation |
| BIRC2 (cIAP1) | E3 ubiquitin ligase that targets NIK for degradation | Inhibitors of cIAP1/2 are used to activate non-canonical NF-kappaB |
| BIRC3 (cIAP2) | E3 ubiquitin ligase that targets NIK for degradation | Similar to cIAP1, regulates NIK stability |
| CD40 | Receptor that triggers non-canonical NF-kappaB activation in B cells | Studied in B-cell malignancies and immune responses |
| LTBR | Lymphotoxin-beta receptor that activates the non-canonical pathway | Important for lymphoid organogenesis |
| BAFFR (TNFRSF13C) | Receptor for BAFF that activates non-canonical NF-kappaB in B cells | Target in autoimmune diseases and B-cell lymphomas |
| S100A14 | Promotes colorectal cancer progression via UPF1-mediated activation of non-canonical NF-kappaB | Potential biomarker and therapeutic target in colorectal cancer |
| UPF1 | RNA helicase involved in S100A14-mediated activation of non-canonical NF-kappaB | Modulates pathway activation in cancer |
| NFKB1 | Canonical NF-kappaB subunit that can crosstalk with non-canonical pathway | Context-dependent roles in immune regulation |
| TNFSF13B (BAFF) | Ligand for BAFFR that activates non-canonical NF-kappaB | Therapeutic target in autoimmune diseases |
| CXCL13 | Chemokine induced by non-canonical NF-kappaB in lymphoid tissues | Associated with immune-hot tumors and immunotherapy response |
How Is positive regulation of non-canonical NF-kappaB signal transduction Regulated?
The positive regulation of non-canonical NF-kappaB signaling is tightly controlled by multiple mechanisms. The stability of NIK is the most critical checkpoint: TRAF2, TRAF3, and cIAP1/2 form a complex that constantly ubiquitinates NIK, targeting it for proteasomal degradation. Upon receptor activation, TRAF3 is degraded, allowing NIK to accumulate. Additionally, negative feedback loops involving TRAF3 and cIAP1/2 can be downregulated by various stimuli, further enhancing pathway activation. Crosstalk with other signaling pathways, such as the canonical NF-kappaB pathway and MAPK cascades, can also modulate the strength and duration of non-canonical signaling. In disease contexts, such as HIV infection, pharmacological agents like SMAC mimetics can stabilize NIK and activate the pathway, which is being explored for latency reversal.
positive regulation of non-canonical NF-kappaB signal transduction and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MAP3K14 (NIK) | Hodgkin lymphoma, non-Hodgkin lymphoma | Knockout or point-mutation in lymphoma cell lines; xenograft models |
| NFKB2 | Lymphoid malignancies, immunodeficiency | Knock-in of patient mutations in B cells; mouse models |
| TRAF3 | Hodgkin lymphoma, non-Hodgkin lymphoma | Knockout in B-cell lines; CRISPR screening |
| S100A14 | Colorectal cancer, anti-PD-1 resistance | Overexpression and knockout in colorectal cancer cell lines; syngeneic mouse models |
| RELB | Hodgkin lymphoma | Overexpression in lymphoid cell lines; knockout in mouse models |
Lymphoid malignancies
Constitutive activation of the non-canonical NF-kappaB pathway is a hallmark of several lymphoid malignancies, including Hodgkin lymphoma and non-Hodgkin lymphoma. In Hodgkin lymphoma, genetic alterations such as mutations in NFKB2, TRAF3, or cIAP1/2 lead to persistent NIK stabilization and p52-RelB nuclear activity, driving survival and proliferation of malignant cells. Similarly, in non-Hodgkin lymphoma, non-canonical NF-kappaB signaling plays a pivotal role in tumorigenesis, and its inhibition is being explored as a therapeutic strategy. These findings underscore the importance of positive regulation of this pathway in cancer biology.
HIV latency and shock-and-kill strategies
The non-canonical NF-kappaB pathway is dynamically modulated during HIV infection and is a target for shock-and-kill strategies aimed at purging latent viral reservoirs. Activation of this pathway can reactivate latent HIV-1 provirus in resting CD4+ T cells, making infected cells visible to the immune system. Pharmacological modulators of NIK, such as SMAC mimetics, are being investigated to enhance non-canonical NF-kappaB signaling and reverse latency. Thus, positive regulation of this pathway has direct implications for HIV cure research.
Tuberculosis and immune impairment
Impaired non-canonical NF-kappaB signaling is associated with disseminated tuberculosis and compromised T cell immunity. In patients with disseminated tuberculosis, reduced activation of the non-canonical pathway in T cells correlates with exhaustion and poor immune control of Mycobacterium tuberculosis. This suggests that positive regulation of this pathway is necessary for effective host defense, and strategies to enhance it could improve tuberculosis outcomes.
Colorectal cancer and immunotherapy resistance
Recent evidence links S100A14-mediated activation of non-canonical NF-kappaB signaling to colorectal cancer progression and resistance to anti-PD-1 immunotherapy. S100A14 promotes UPF1-dependent activation of the pathway, leading to an immunosuppressive tumor microenvironment and poor response to immune checkpoint blockade. Targeting this axis may overcome resistance and improve immunotherapy efficacy in colorectal cancer.
From positive regulation of non-canonical NF-kappaB signal transduction-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does knockout of NIK reduce non-canonical NF-kappaB activation? | CRISPR knockout of MAP3K14 in B-cell lymphoma lines |
| Does a point mutation in NFKB2 affect p100 processing? | CRISPR point mutation knock-in of NFKB2 in HEK293T or B cells |
| Does overexpression of S100A14 enhance non-canonical NF-kappaB signaling? | CRISPR overexpression (CRISPRa) or lentiviral overexpression in colorectal cancer cells |
| Does a tagged NIK knock-in allow real-time tracking of NIK stabilization? | CRISPR knock-in of fluorescent or epitope tag at endogenous MAP3K14 locus |
| Does knockout of TRAF3 activate non-canonical NF-kappaB? | CRISPR knockout of TRAF3 in immune cells |
| Does a reporter knock-in measure p52-RelB transcriptional activity? | CRISPR knock-in of luciferase or GFP under NF-kappaB target promoter |
How to Study the positive regulation of non-canonical NF-kappaB signal transduction Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss-of-function effects on pathway activity | Identify essential genes like NIK, IKKalpha |
| CRISPR point mutation | Effect of specific amino acid changes | Study phosphorylation sites in p100 |
| CRISPR knock-in (tag) | Protein localization and stability | Track NIK stabilization in live cells |
| CRISPR activation (CRISPRa) | Endogenous overexpression | Model S100A14-driven colorectal cancer |
| RNA-seq | Transcriptional changes | Identify NF-kappaB target genes |
| Proteomics | Protein abundance and modifications | Measure p100 processing and NIK levels |
| Immunofluorescence | Nuclear translocation of p52-RelB | Visualize pathway activation |
| CRISPR library screening | Genome-wide regulators | Discover novel modulators of non-canonical NF-kappaB |
CRISPR knockout and point mutation
CRISPR-Cas9 knockout of key genes such as MAP3K14, CHUK, or TRAF3 is widely used to dissect the non-canonical NF-kappaB pathway. Knockout of NIK abolishes pathway activation, while knockout of TRAF3 leads to constitutive activation. Point mutations can be introduced to study specific phosphorylation sites, such as those in p100 required for processing. These models help establish causality between gene function and pathway activity.
Knock-in and tagged knock-in
Knock-in of epitope tags (e.g., FLAG, HA) or fluorescent proteins (e.g., GFP) at endogenous loci allows real-time monitoring of protein stability and localization. For example, a GFP-NIK knock-in can track NIK stabilization upon ligand stimulation. Similarly, a luciferase reporter knock-in under the control of p52-RelB target promoters can quantify pathway activity in live cells.
Overexpression and CRISPR activation
Overexpression of pathway components, such as NIK or RelB, or of upstream regulators like S100A14, can enhance non-canonical NF-kappaB signaling and model disease states. CRISPR activation (CRISPRa) enables endogenous overexpression without artifacts of transient transfection, making it ideal for studying dose-dependent effects.
Library screening and bioinformatics
Genome-wide CRISPR knockout or activation screens can identify novel regulators of the non-canonical NF-kappaB pathway. Combined with RNA-seq and proteomics, these screens reveal transcriptional and post-translational networks. Bioinformatics analyses of patient datasets, such as those from Hodgkin lymphoma, can uncover mutations and expression signatures associated with pathway activation.
How CRISPR Can Be Used to Study GO:1901224 positive regulation of non-canonical NF-kappaB signal transduction
Knockout
CRISPR knockout is used to delete genes such as MAP3K14 (NIK), CHUK (IKKalpha), or TRAF3 to determine their requirement for non-canonical NF-kappaB activation. For example, NIK knockout abolishes p100 processing and p52-RelB nuclear translocation, confirming its essential role. Knockout of TRAF3, a negative regulator, leads to constitutive pathway activation, demonstrating its role in restraining signaling.
Point Mutation
Point mutations can be introduced to study specific residues critical for pathway function. For instance, mutation of serine residues in the C-terminus of p100 that are phosphorylated by IKKalpha blocks its processing to p52. Such models help define the precise molecular requirements for positive regulation.
Knock-in
Knock-in of reporter genes or tags allows real-time monitoring of pathway components. A GFP-NIK knock-in enables visualization of NIK stabilization upon ligand stimulation. Similarly, a luciferase reporter knock-in driven by a p52-RelB-responsive promoter provides a quantitative readout of pathway activity.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression can elevate levels of pathway activators like NIK, RelB, or S100A14. Overexpression of S100A14 in colorectal cancer cells enhances non-canonical NF-kappaB signaling and promotes anti-PD-1 resistance, modeling the human disease.
How EDITGENE Supports positive regulation of non-canonical NF-kappaB signal transduction Research
Researchers studying positive regulation of non-canonical NF-kappaB signal transduction-related genes often need to determine whether a candidate gene is causally involved in pathway activation, and to dissect the molecular mechanisms by which it contributes to disease. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of non-canonical NF-kappaB signal transduction research.
Frequently Asked Questions About positive regulation of non-canonical NF-kappaB signal transduction
What is GO:1901224?
GO:1901224 is a Gene Ontology term for positive regulation of non-canonical NF-kappaB signal transduction, describing any process that activates or increases the non-canonical NF-kappaB cascade.
What genes are involved in positive regulation of non-canonical NF-kappaB signaling?
Key genes include MAP3K14 (NIK), CHUK (IKKalpha), NFKB2 (p100/p52), RELB, TRAF2, TRAF3, BIRC2 (cIAP1), and BIRC3 (cIAP2).
How is the non-canonical NF-kappaB pathway activated?
It is activated by ligands such as CD40L, BAFF, or lymphotoxin-beta, which stabilize NIK, leading to IKKalpha activation and p100 processing to p52.
What diseases are associated with non-canonical NF-kappaB signaling?
It is linked to Hodgkin lymphoma, non-Hodgkin lymphoma, HIV latency, disseminated tuberculosis, and colorectal cancer.
What is the difference between canonical and non-canonical NF-kappaB pathways?
The canonical pathway relies on IKKbeta and IkappaBalpha degradation, while the non-canonical pathway depends on NIK, IKKalpha, and p100 processing to p52.
How can I study positive regulation of non-canonical NF-kappaB signaling?
CRISPR knockout, point mutation, knock-in, overexpression, and library screening are common approaches, combined with RNA-seq and proteomics.
What is the role of NIK in non-canonical NF-kappaB signaling?
NIK is the central kinase that, upon stabilization, activates IKKalpha and triggers p100 processing, making it essential for pathway activation.
Is non-canonical NF-kappaB a therapeutic target?
Yes, it is being explored as a target in lymphoid malignancies, HIV latency reversal, and immunotherapy-resistant colorectal cancer.
What cell models are available for non-canonical NF-kappaB research?
EDITGENE provides knockout, point mutation, knock-in, and overexpression cell models for genes in this pathway, as well as CRISPR library screening services.
How does S100A14 activate non-canonical NF-kappaB?
S100A14 promotes UPF1-mediated activation of the non-canonical NF-kappaB pathway, contributing to colorectal cancer progression and anti-PD-1 resistance.
Conclusion
GO:1901224, positive regulation of non-canonical NF-kappaB signal transduction, is a critical biological process that governs immune responses, lymphoid organogenesis, and cell survival. Its dysregulation is implicated in a spectrum of diseases, from lymphoid malignancies to infectious diseases and solid tumors. Understanding the molecular mechanisms and key genes involved provides a foundation for developing targeted therapies. EDITGENE offers comprehensive CRISPR services to facilitate research into this pathway, from knockout and point mutation models to library screening and bioinformatics.
References
- 1. Jenkins BH et al.. 2025. Single cell and spatial analysis of immune-hot and immune-cold tumours identifies fibroblast subtypes associated with distinct immunological niches and positive immunotherapy response.. Mol Cancer 24(1):3 PMID: 39757146
- 2. Chandrasekar AP et al.. 2024. Dynamic modulation of the non-canonical NF-κB signaling pathway for HIV shock and kill.. Front Cell Infect Microbiol 14:1354502 PMID: 38505285
- 3. Weniger MA et al.. 2016. NF-κB deregulation in Hodgkin lymphoma.. Semin Cancer Biol 39:32-9 PMID: 27221964
- 4. Krappmann D et al.. 2016. Mechanisms of NF-κB deregulation in lymphoid malignancies.. Semin Cancer Biol 39:3-14 PMID: 27262792
- 5. Tan L et al.. 2026. S100A14 promotes colorectal cancer progression and anti-PD-1 resistance via UPF1-mediated activation of the non-canonical NF-κB signaling.. Cell Death Dis 17(1) PMID: 42350366
- 6. Liu M et al.. 2015. Non-canonical NF-κB Plays a Pivotal Role in Non-Hodgkin's Lymphoma.. Cell Biochem Biophys 72(3):681-5 PMID: 27352187
- 7. Dhillon B et al.. 2019. The Evolving Role of TRAFs in Mediating Inflammatory Responses.. Front Immunol 10:104 PMID: 30778351
- 8. Jiang J et al.. 2024. Disseminated tuberculosis is associated with impaired T cell immunity mediated by non-canonical NF-κB pathway.. J Infect 89(3):106231 PMID: 39032519
